Piyali  Mukherjee

Dr. Piyali Mukherjee


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
JCJung-Hyun Choi
Jung-Hyun Choi
JSJaime Correia de Sousa
Jaime Correia de Sousa
MFMonica Fletcher
Monica Fletcher
Giovanni GabuttiGiovanni Gabutti
Giovanni Gabutti
LHLauriane Harrington
Lauriane Harrington
SMStefania Maggi
Stefania Maggi
Despite the implementation of effective paediatric vaccination programmes, pertussis remains a global health problem. Disease epidemiology has changed over time, shifting towards the adolescent and adult populations. In adults, the true burden of pertussis is greatly underestimated and pertussis vaccine coverage rates are suboptimal, including individuals with chronic conditions. Here, we report the outcomes of a virtual international scientific workshop to assess the evidence on the burden of pertussis in older adults and identify potential solutions to improve uptake of pertussis vaccines. In adults, pertussis is underdiagnosed in part due to atypical or milder clinical presentation and the lack of testing and case confirmation. However, contemporary epidemiological data denoted an increase in the burden of pertussis among adolescents and adults. This might be related to a variety of reasons including the waning of immunity over time, the lack of booster vaccination, and the improved diagnostic methods that led to increased recognition of the disease in adults. Pertussis sequelae can be severe in older adults, particularly those with existing chronic medical conditions, and the vulnerability of these groups is further enhanced by low pertussis vaccine coverage. Possible measures to increase vaccine uptake include strengthening and harmonisation of immunisation guidelines, healthcare professionals taking a more active role in recommending pertussis vaccination, involvement of vaccination centres and pharmacies in the vaccination process, and improving knowledge of pertussis burden and vaccine efficacy among the general population.

4 March 2021 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
EAEmmanuel Aris
Emmanuel Aris
LHLauriane Harrington
Lauriane Harrington
ABAmit Bhavsar
Amit Bhavsar
JSJason C. Simeone
Jason C. Simeone
ARAnna Ramond
Anna Ramond
PMPiyali Mukherjee
Piyali Mukherjee
Chronic obstructive pulmonary disease (COPD) may increase the risk and severity of pertussis infection. Health care resource utilization (HCRU) and direct medical costs (DMC) of treating pertussis among patients with COPD are unknown. Reported incidence of pertussis among individuals aged ≥ 50 years with COPD was assessed in Clinical Practice Research Datalink and Hospital Episode Statistics databases during 2009–2018 using a retrospective cohort design. HCRU and DMC from the National Health Service perspective were compared between patients with COPD and pertussis and propensity score-matched patients with COPD without pertussis. Seventy-eight new pertussis events were identified among 387 086 patients with COPD aged ≥ 50 years (incidence rate: 4.73; 95% confidence interval 3.74–5.91 per 100 000 person-years). HCRU and DMC were assessed among 67 patients with COPD and pertussis and 267 matched controls. During the month before the pertussis diagnosis, the rates of general practitioner (GP)/nurse visits (4289 vs. 1774 per 100 patient-years) and accident and emergency visits (182 vs. 18 per 100 patient-years) were higher in the pertussis cohort; GP/nurse visits (2935 vs. 1705 per 100 patient-years) were also higher during the following 2 months (all p < 0.001). During the month before the pertussis diagnosis, annualized per-patient total DMC were £2012 higher in the pertussis cohort (£3729 vs. £1717; p < 0.001); during the following 2 months, they were £2407 higher (£5498 vs. £3091; p < 0.001). In conclusion, a pertussis episode among individuals with COPD resulted in significant increases in HCRU and DMC around the pertussis event.

2 April 2020 in Expert Review of Vaccines
Verified
Journal Article
Open access
WKWalid Kandeil
Walid Kandeil
MSMiloje Savic
Miloje Savic
MCMaria Angeles Ceregido
Maria Angeles Ceregido
AGAdrienne Guignard
Adrienne Guignard
AKAnastasia Kuznetsova
Anastasia Kuznetsova
PMPiyali Mukherjee
Piyali Mukherjee
Introduction: Maternal immunization with reduced antigen content tetanus-diphtheria-acellular pertussis (Tdap)-containing vaccines has been recommended to prevent infant pertussis. However, maternal antibodies may interfere with infant responses to routine immunization with diphtheria-tetanus-acellular pertussis (DTaP)-containing vaccines, raising concerns of suboptimal protection after infant vaccination. We performed a narrative literature review to assess whether blunting occurs regardless of the manufacturer of maternal and infant vaccines. Because internationally agreed correlates of protection are lacking, the clinical significance of blunting is not yet fully understood. We have reviewed the evidence available to date. Areas Covered: Thirteen studies that evaluated blunting after maternal immunization and infant primary/booster series were identified. Blunting was observed with various combinations of Tdap- and DTaP-containing vaccines for maternal and pediatric immunization. Studies assessing the effectiveness of maternal Tdap immunization beyond the primary infant immunization series in England and in the United States suggested no evidence of a clinically relevant blunting effect so far. Expert Opinion: This review indicates that the phenomenon of blunting does not depend on the manufacturer/brand of the pertussis-containing vaccines used for immunizing mothers or children. Currently, there is no epidemiological evidence that children whose mothers received Tdap are at increased risk of pertussis after pediatric vaccinations, although longer follow-up is required.

3 June 2018 in Expert Review of Vaccines
Verified
Journal Article
Open access
SPScott Preiss
Scott Preiss
PCPornthep Chanthavanich
Pornthep Chanthavanich
LCLin Chen
Lin Chen
CMCinzia Marano
Cinzia Marano
PBPhilippe Buchy
Philippe Buchy
PMPiyali Mukherjee
Piyali Mukherjee
Introduction: Fifteen million people each year receive post-exposure prophylaxis (PEP) to prevent rabies, yet the disease remains neglected and highly under-reported. Areas covered: In this systematic literature review, we assessed the immunogenicity, efficacy, and safety of a purified chick embryo cell-culture rabies vaccine (PCECV) for PEP against rabies by intramuscular (IM) or intradermal (ID) administration. We performed meta-analyses to compare immunogenicity according to the route of vaccine administration, study population, and PEP regimen, such as number of doses, and concomitant rabies immunoglobulin. Expert commentary: There were 54 estimates of immune responses to vaccination, which showed that in the overall population, after starting PEP with PCECV by the IM or ID route (≥2.5 IU per dose), almost all individuals had rabies virus neutralizing antibody (RVNA) titers above the World Health Organization (WHO) recommended serological threshold for an adequate immune response to vaccination (RVNA ≥0.5 IU/ml by day 14). In the overall population, PCECV had an acceptable safety profile. However, given that there are 59,000 human rabies deaths reported annually, the challenge is to improve access to PCECV for PEP against human rabies.

1 May 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
CTChao-Hsiun Tang
Chao-Hsiun Tang
WCWen-fang Cheng
Wen-fang Cheng
JJJhih-Hua Jiang
Jhih-Hua Jiang
SYSan-Lin You
San-Lin You
LHLee-Wen Huang
Lee-Wen Huang
CLChrista Lee
Christa Lee
Objective: Three vaccines are available to Taiwanese young girls for cervical cancer (CC) prevention. Herewe evaluate the cost-effectiveness of the two-dose (2D) AS04-adjuvanted HPV-16/18 vaccine (2D-AS04-HPV-16/18v)+screening compared with a screening programme alone, with 2D human papillomavirus 6/11/16/18 vaccine(2D-4vHPVv)+screening, and with 2D/three-dose (3D) human papillomavirus 6/11/16/18/31/33/45/52/58 vaccine(9vHPVv)+screening, for Taiwan universal mass vaccination. Methods: A static Markov cohort model simulated thenatural history of human papillomavirus (HPV) infection and CC screening for a 12-year-old cohort of Taiwanese girls(N=120,000). The model ran in 1-year cycles over the cohort’s lifetime. Vaccine efficacy irrespective of HPV typewas considered in the analysis for each vaccine. Input data were obtained from published literature, local databases,government reports and websites, and expert opinion. The analysis incorporated direct medical costs only, with anannual discount rate of 3.0%. The threshold was determined as 1 Gross Domestic Product per capita (New Taiwandollar [NT$] 727,818; year 2016). Results: The 2D-AS04-HPV-16/18v+screening yielded 0.0365 quality-adjusted lifeyear (QALY) gained at an additional cost of NT$ 5,770 per person compared with the screening programme alone. Thisresulted in an incremental cost-effectiveness ratio well below the threshold. Compared with 2D-4vHPVv+screening and2D/3D-9vHPVv+screening, discounted results demonstrated additional QALYs gained at lower cost for 2D-AS04-HPV-16/18v+screening, making it dominant over both 2D-4vHPVv+screening and 2D/3D-9vHPVv+screening. Conclusions:Vaccinating Taiwanese girls with 2D-AS04-HPV-16/18v in addition to screening to prevent CC is cost-effectivecompared with using a screening programme alone and the dominant option compared with 2D-4vHPVv+screeningand 2D/3D-9vHPVv+screening.

4 May 2021 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
TWTom M. A. Wilkinson
Tom M. A. Wilkinson
PSPeter Van Den Steen
Peter Van Den Steen
BCBrigitte Cheuvart
Brigitte Cheuvart
NBNathalie Baudson
Nathalie Baudson
MDMonique Dodet
Monique Dodet
PMPiyali Mukherjee
Piyali Mukherjee
Pertussis is underdiagnosed and underreported in adults and patients with underlying conditions. Patients with chronic obstructive pulmonary disease (COPD) may be at increased risk of severe pertussis. Understanding the true prevalence of pertussis infections in such patients is important. We therefore evaluated the seroprevalence of anti-pertussis toxin (PT) antibodies in a cohort of 40–85-year-old patients diagnosed with moderate, severe or very severe COPD enrolled (between June 2011 and June 2012) in the prospective, observational “Acute Exacerbation and Respiratory InfectionS in COPD” (AERIS; NCT01360398) study, conducted in England. Serum anti-PT antibodies were measured in 104 patients using an enzyme-linked immunosorbent assay on samples collected 12 months (M12) and 24 months (M24) after enrollment. Overall, 14/104 (13.5%) patients had anti-PT concentrations ≥50 IU/mL at M12 or M24, indicative of exposure to Bordetella pertussis during the preceding 2–3 years. Of these, 6/104 (5.8%) had anti-PT ≥70 IU/mL, of whom 3/104 (2.9%) had anti-PT ≥120 IU/mL, indicative of exposure within 12 and 6 months, respectively. These results show a high circulation of B. pertussis in 40–85-year-old patients with moderate, severe or very severe COPD in England between 2012 and 2014, and call for enhanced immunization to prevent pertussis infections in such patients.